---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-046411"
form_type: "8-K"
ticker: "ALLR"
cik: "0001860657"
company_name: "Allarity Therapeutics, Inc."
filed_at: "2026-04-22T23:59:59+00:00"
generated_at: "2026-05-15T04:56:02.287800+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Allarity Therapeutics presents AACR posters on stenoparib for colorectal cancer and ovarian cancer survival

## Summary
- Poster 2: stenoparib blocks WNT/β-catenin signaling and inhibits growth of colorectal cancer cell lines at clinically relevant concentrations.
- Poster 1: Highest stenoparib DRP® scores are associated with enhanced overall survival in phase 2 ovarian cancer trial (NCT03878849).
- CEO Thomas Jensen highlights stenoparib potential in colorectal cancer, a large area of unmet need in oncology.
- DRP® companion diagnostic platform may identify patients most likely to achieve extended survival with stenoparib.

## SEC filing metadata
- accession: 0001213900-26-046411
- form_type: 8-K
- ticker: ALLR
- cik: 0001860657
- company_name: Allarity Therapeutics, Inc.
- filed_at: 2026-04-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860657/000121390026046411/0001213900-26-046411-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860657/000121390026046411/ea0287156-8k_allarity.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-046411
- JSON: https://secwatch.observer/filing/0001213900-26-046411.json
- Plain text: https://secwatch.observer/filing/0001213900-26-046411.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.